TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848)

被引：136

作者：

Weeratna, RD ^{[1
]}

Makinen, SR ^{[1
]}

McCluskie, MJ ^{[1
]}

Davis, HL ^{[1
]}

机构：

[1] Coley Pharmaceut Grp, Ottawa, ON K2K 3A2, Canada

来源：

VACCINE | 2005年 / 23卷 / 45期

关键词：

CpG ODN; R-848; vaccine adjuvants; TLR ligands;

D O I：

10.1016/j.vaccine.2005.06.024

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

TLR ligands that mimic pathogen associated molecular pat terns and activate immune cells via Toll-like receptors (TLRs) are being developed for use in humans as therapy against a variety of diseases as well as vaccine adjuvants. These include imidazoquinoline compounds such as Imiquimod and Resiquimod (R-848) that bind to TLR7 and 8, as well as CpG oligodeoxynucleotides (CpG ODN) that bind to TLR9. This Study was aimed at comparing CpG ODN and R-848 for their potential use as vaccine adjuvants and to determine whether there are additive or synergistic effects when they are used together. Using HBsAg as a model antigen in mice, we show CpG ODN to be superior to R-848 for augmenting both humoral and cell mediated immune responses. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：5263 / 5270

页数：8

共 65 条

[1]

Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO

[2]

2-U

[3] Toll-like receptors: critical proteins linking innate and acquired immunity [J].